Skip to main navigation Skip to search Skip to main content

Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

  • J Naidoo
  • , SJ Antonia
  • , YL Wu
  • , BC Cho
  • , P Thiyagarajah
  • , H Mann
  • , MD Newton
  • , C Faivre-Finn

Research output: Contribution to journal › Meeting Abstract › peer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume40
Issue number16
Publication statusPublished - 1 Jun 2022

Cite this